Castle Biosciences Reports Q2 2026 Financial Results

What Happened
Castle Biosciences, Inc. announced its financial results for the quarter ended June 30, 2026 in a press release issued July 30, 2026 and filed an 8-K under Item 2.02 (Results of Operations and Financial Condition). The company also made an investor slide presentation available under Item 7.01 (Regulation FD disclosure). The press release is attached as Exhibit 99.1 and the slide deck as Exhibit 99.2 to the filing.

Key Details

• Date of filing and disclosures: July 30, 2026.
• Reporting period: quarter ended June 30, 2026 (Q2 2026).
• Exhibits provided: Exhibit 99.1 (press release) and Exhibit 99.2 (slide presentation).
• The 8-K notes the press release/slide deck are furnished under Regulation FD and are not deemed “filed” for Section 18 liability purposes.
• Filing signed by Frank Stokes, Chief Financial Officer.

Why It Matters
This 8-K signals that Castle has released its quarterly results and investor materials; investors should review the attached press release and slide deck for revenue, earnings, guidance, cash position, and any management commentary. The Regulation FD disclosure means the same information was broadly distributed and may be used in investor meetings, so material financial details will be found in the linked exhibits rather than in the body of the 8-K.